A61P 5/42
For decreasing, blocking or antagonising the activity of mineralocorticosteroids
Official title: for decreasing, blocking or antagonising the activity of mineralocorticosteroids
A61P5/42 (For decreasing, blocking or antagonising the activity of mineralocorticosteroids) appears on 162 US grants and 241 published applications in this corpus.
Search patents in A61P- Granted patents
- 162
- Published applications
- 241
- Assignees
- 113
- Inventors
- 634
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 3 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 5 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 4 |
| 2004 | 3 | 10 |
| 2005 | 3 | 7 |
| 2006 | 1 | 10 |
| 2007 | 3 | 14 |
| 2008 | 1 | 14 |
| 2009 | 4 | 22 |
| 2010 | 4 | 28 |
| 2011 | 15 | 18 |
| 2012 | 12 | 15 |
| 2013 | 19 | 14 |
| 2014 | 10 | 9 |
| 2015 | 11 | 9 |
| 2016 | 15 | 16 |
| 2017 | 13 | 10 |
| 2018 | 6 | 8 |
| 2019 | 5 | 4 |
| 2020 | 7 | 6 |
| 2021 | 2 | 5 |
| 2022 | 3 | 5 |
| 2023 | 1 | 2 |
| 2024 | 0 | 2 |
| 2025 | 4 | 3 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- 3-phenylpropylamine derivative21 Apr 2026US 12,606,533 B2Daiichi Sankyo Company, Limited
- Humanized anti-ACTH antibodies and use thereof30 Sep 2025US 12,428,475 B2H. Lundbeck A.S.
- Composition, comprising thiamine derivative, for prevention or treatment of hypercortisolemia5 Aug 2025US 12,377,111 B2Kyungpook National University Industry-Academic Cooperation Foundation
- Anti-ACTH antibodies and use thereof8 Jul 2025US 12,351,627 B2H. Lundbeck A.S.
- Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism21 Jan 2025US 12,201,632 B2Strongbridge Dublin Limited
- Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor10 Sep 2026US 2026/0265249 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof16 Jul 2026US 2026/0200931 A1Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Humanized anti-acth antibodies and use thereof9 Jul 2026US 2026/0193344 A1H. Lundbeck A.S.
- Once daily aldosterone synthase inhibitor (r)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine7 May 2026US 2026/0124184 A1Damian Pharma AG
- 3-phenylpropylamine derivative20 Nov 2025US 2025/0353824 A1Daiichi Sankyo Company, Limited
Most cited
By later US patents
- Fused ring azadecalin glucocorticoid receptor modulators67US 7,928,237 B2Corcept Therapeutics, Inc. · 2011
- Tricyclic benzazepine vasopressin antagonists62US 5,753,648 AAmerican Cyanamid Company · 1998
- Bismethylene-17A carbolactones and related uses53US 7,960,368 B2Everstra, Inc. · 2011
- Physiologically active porcine peptide (CNP-53)26US 5,340,920 A1994
- Fused ring azadecalin glucocorticoid receptor modulators25US 8,557,839 B2Corcept Therapeutics, Inc. · 2013